Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Follow us on social media
